Gebo KA - Search Results

1

Health insurance coverage for persons in HIV care, 2006-2012.

Yehia BR, Fleishman JA, Agwu AL, Metlay JP, Berry SA, Gebo KA; HIV Research Network. Yehia BR, et al. Among authors: gebo ka. J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):102-6. doi: 10.1097/QAI.0000000000000251. J Acquir Immune Defic Syndr. 2014. PMID: 24977377 Free PMC article.

2

Costs of HIV medical care in the era of highly active antiretroviral therapy.

Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moore RD. Gebo KA, et al. AIDS. 1999 May 28;13(8):963-9. doi: 10.1097/00002030-199905280-00013. AIDS. 1999. PMID: 10371178

3

Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy.

Gebo KA, Diener-West M, Moore RD. Gebo KA, et al. J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):143-52. doi: 10.1097/00126334-200106010-00009. J Acquir Immune Defic Syndr. 2001. PMID: 11404536

4

Hospitalization rates differ by hepatitis C satus in an urban HIV cohort.

Gebo KA, Diener-West M, Moore RD. Gebo KA, et al. J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):165-73. doi: 10.1097/00126334-200310010-00006. J Acquir Immune Defic Syndr. 2003. PMID: 14526205

5

The HIV Research Network: a unique opportunity for real time clinical utilization analysis in HIV.

Gebo KA, Moore RD, Fleishman JA. Gebo KA, et al. Hopkins HIV Rep. 2003 Nov;15(6):5-6. Hopkins HIV Rep. 2003. PMID: 14974424 No abstract available.

6

Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection.

Gebo KA, Gallant JE, Keruly JC, Moore RD. Gebo KA, et al. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1028-33. doi: 10.1097/00126334-200408150-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15247555

7

Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001.

Gebo KA, Fleishman JA, Conviser R, Reilly ED, Korthuis PT, Moore RD, Hellinger J, Keiser P, Rubin HR, Crane L, Hellinger FJ, Mathews WC; HIV Research Network. Gebo KA, et al. J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):96-103. doi: 10.1097/00126334-200501010-00017. J Acquir Immune Defic Syndr. 2005. PMID: 15608532

8

An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002.

Moore RD, Keruly JC, Gebo KA, Lucas GM. Moore RD, et al. Among authors: gebo ka. J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):195-8. J Acquir Immune Defic Syndr. 2005. PMID: 15905736

9

Patterns of diagnoses in hospital admissions in a multistate cohort of HIV-positive adults in 2001.

Betz ME, Gebo KA, Barber E, Sklar P, Fleishman JA, Reilly ED, Christopher Mathews W; HIV Research Network. Betz ME, et al. Among authors: gebo ka. Med Care. 2005 Sep;43(9 Suppl):III3-14. doi: 10.1097/01.mlr.0000175632.83060.eb. Med Care. 2005. PMID: 16116304

10

Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.

Rutstein RM, Gebo KA, Flynn PM, Fleishman JA, Sharp VL, Siberry GK, Spector SA. Rutstein RM, et al. Among authors: gebo ka. Med Care. 2005 Sep;43(9 Suppl):III15-22. doi: 10.1097/01.mlr.0000175636.34524.b9. Med Care. 2005. PMID: 16116305 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

265 results

Search Page

Filters